Gene mutations accumulating in cells are typical of the development of cancer. Finnish researchers found that a similar accumulation of mutations occurs also in some patients with rheumatoid arthritis.
Researchers have developed a two-pronged approach to blood cancer treatment: 1) attacking cancer cells directly and/or 2) driving them from the nurturing bone marrow environment into the peripheral blood streams, where they are more vulnerable (for example, to chemotherapy).
While it's widely held that tumors can produce blood vessels to support their growth, scientists now have evidence that cells key to blood vessel formation can also produce tumors and enable their spread.
Researchers studying a DNA-cutting enzyme with a crucial role in regulating the structure of genes have discovered a broad role for its cutting activity in driving abnormal genetic rearrangements called translocations that cause cancer, including leukemias and solid tumors.
Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies. An existing drug might be repurposed to treat these leukemias, and the new understanding of the molecular mechanisms at work may offer clues to other drugs yet to be developed.
A team of cancer researchers at the George Washington University Cancer Center published research looking at the underlying mechanisms of resistance to the drug, Ibrutinib, which is used to treat patients with mantle cell lymphoma.
Patients who have aggressive prostate cancer could be identified by a highly accurate and simple blood test, according to an early study by Queen Mary University of London (QMUL).
A University of Colorado Cancer Center paper published today in the journal Cancer Cell challenges existing understanding of potential therapeutic targets in MLL-translocation leukemia. Specifically, the study shows that within the family of MLL-related proteins, MLL2 and not MLL is the most appropriate target for drugs challenging the disease. In other words, drug developers aiming at MLL may have been missing slightly to one side of the real target.
A clinical trial compared new and traditional treatments for iron-deficiency anemia and determined that the traditional treatment, ferrous sulfate, can more effectively treat the anemia in young children.
Identification of new pathogens requires a rapid response from industry to develop new tests and the FDA to assess test safety and efficacy. A report in The Journal of Molecular Diagnostics evaluates the new OpenArray system that offers simultaneous detection of multiple viruses, bacteria, and protozoan pathogens in human blood samples. Investigators determined that this system is a promising tool for flexible, fast, and accurate blood screening.